Zenas BioPharma (ZBIO) Income towards Parent Company (2023 - 2026)

Zenas BioPharma's Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$81.0 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 141.23% year-over-year to -$81.0 million in Q1 2026; TTM through Mar 2026 was -$435.8 million, a 168.49% decrease from a year earlier, with the FY2025 full-year figure at -$388.4 million, down 147.43% from the prior year.
• Income towards Parent Company rose to -$81.0 million in Q1 2026 per ZBIO's latest filing, from -$251.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $35.6 million in Q3 2023 and bottomed at -$251.1 million in Q4 2025.
• The 4-year median for Income towards Parent Company is -$38.6 million (2024), against an average of -$56.7 million.
• Biggest YoY gain for Income towards Parent Company was 20.77% in 2025; the steepest drop was 381.33% in 2025.
• Year by year, Income towards Parent Company stood at -$32.9 million in 2023, then slumped by 58.77% to -$52.2 million in 2024, then tumbled by 381.33% to -$251.1 million in 2025, then soared by 67.75% to -$81.0 million in 2026.
• Per Business Quant, the three latest ZBIO Income towards Parent Company figures stand at -$81.0 million (Q1 2026), -$251.1 million (Q4 2025), and -$51.5 million (Q3 2025).